SCHEMBL7252826

SCHEMBL7252826

c1ccc2c(c1)nc1ccc3occcc3c12.c1coc2cc3nc4ccccc4c3cc2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.37
ESR2 Q92731 2/20 0.37
CDK4 P11802 1/20 0.36
CCND1 P24385 1/20 0.36
KDM4E B2RXH2 7/20 0.34
TDP1 Q9NUW8 5/20 0.34
POLB P06746 4/20 0.34
L3MBTL1 Q9Y468 3/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
MAPT P10636 2/20 0.34
RECQL P46063 2/20 0.34
ALDH1A1 P00352 6/20 0.34
HPGD P15428 5/20 0.34
GLA P06280 3/20 0.34
HSD17B10 Q99714 3/20 0.34
GAA P10253 2/20 0.34
ADORA2A P29274 2/20 0.34
TP53 P04637 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4493170 0.89 ESR1 (0.45) ESR1ESR2KDM4ETDP1POLB
SCHEMBL4501863 0.87 CDK4 (0.44) ESR1CDK4CCND1KDM4ETDP1
SCHEMBL4892024 0.80 CDK4 (0.41) ESR1CDK4CCND1KDM4ETDP1
SCHEMBL30557325 0.80 CDK4 (0.41) ESR1CDK4CCND1KDM4ETDP1
SCHEMBL9307675 0.77 ESR1 (0.44) ESR1ESR2KDM4ETDP1POLB
SCHEMBL7532714 0.73 ALDH1A1 (0.47) ESR1ESR2KDM4ETDP1POLB
SCHEMBL4501936 0.70 CDK4 (0.43) ESR1CDK4CCND1KDM4ETDP1
SCHEMBL420380 0.69 CDK4 (0.54) ESR1ESR2CDK4CCND1KDM4E
SCHEMBL4495841 0.68 MAPK10 (0.42) ESR1KDM4ETDP1POLBL3MBTL1
SCHEMBL29588824 0.68 MAPK10 (0.42) ESR1KDM4ETDP1POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6534496-B1 Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or TAKEDA CHEMICAL INDUSTRIES, INC. (JP) 2003-03-18 US disclosed